Regorafenib: start low and go slow.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.The oncologist · 2019
   Trial
2. Optimized Dosing of Regorafenib in Patients With Metastatic Colorectal Cancer: A Practical Guide for Oncologists, Advanced Practice Providers, and Pharmacists.Journal of the advanced practitioner in oncology · 2025
   Review
3. Regorafenib monotherapy as the later-line treatment for elderly patients with metastatic colorectal cancer: a multicenter real-world study.Journal of gastrointestinal oncology · 2024
   Article
4. Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence.Future oncology (London, England) · 2024
   Article
5. Appropriate dose of regorafenib based on body weight of colorectal cancer patients: a retrospective cohort study.BMC cancer · 2023
   Article
6. Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis.Therapeutic advances in medical oncology · 2020
   Article
7. Regorafenib adjusted dose for Chilean patients with chemoresistant metastatic colorectal cancer: a case series.Ecancermedicalscience · 2018
   Article
8. Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a "me too" drug?Cancer management and research · 2018
   Review
9. Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice.Therapeutic advances in medical oncology · 2017
   Article
10. Author's Reply to Christelle de la Fouchardière: "Regorafenib: Start Low and Go Slow".Targeted oncology · 2016
    Article
11. Comment on: "Regorafenib: Start Low and Go Slow".Targeted oncology · 2016
    Article
12. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.Annals of oncology : official journal of the European Society for Medical Oncology · 2015
    Review
13. Anti-angiogenic agents in metastatic colorectal cancer.World journal of gastrointestinal oncology · 2015
    Review
14. Aggressive Fibromatosis of the Left Mesocolon Mimicking a Gastrointestinal Stromal Tumor: A Case Report.Case reports in oncology
    Article

Corrections and comments

• Commented on by
  Comment on: "Regorafenib: Start Low and Go Slow".2016
• Commented on by
  Author's Reply to Christelle de la Fouchardière: "Regorafenib: Start Low and Go Slow".2016

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as